ASX:SLD

4 stories mentioning ASX:SLDUpdated 34d ago

Every FINWIRES story that references ASX:SLD, newest first.

Saluda Medical Says First Procedures in US Performed with Surgical Paddle Leads, Shares Jump 3%

Saluda Medical (ASX:SLD) said the first procedures in the US using the Evoke CAP24 surgical paddle lead were performed on Friday, July 10, and Tuesday, July 14, according to a Thursday Australian bourse filing.Its Evoke system is designed to treat chronic neuropathic pain by providing spinal cord stimulation (SCS) therapy that senses and measures neural activation to optimize therapy.Its shares jumped 3% in recent trading on Thursday.

ASX:SLD

Asia49d ago

Saluda Medical Fully Draws $25 Million From Second Tranche of Perceptive Credit Facility; Shares Gain 3%

Saluda Medical (ASX:SLD) drew the full $25 million from the second tranche of its credit facility with Perceptive Credit Holdings IV, according to a Wednesday filing with the Australian bourse.In connection with the drawdown, Saluda issued a warrant to Perceptive to purchase 88,000 shares of its common stock at an exercise price of $17 each.The company will use the second-tranche proceeds for general commercial and operating purposes. It said a third tranche of $25 million is available through the end of the year, subject to certain conditions.Saluda Medical shares gained 3% in recent Wednesday trade.

ASX:SLD

Asia50d ago

Saluda Medical's Surgical Paddle Lead Approved by FDA, Shares Soar 18%

Saluda Medical (ASX:SLD) said the US Food and Drug Administration (FDA) approved its CAP24 surgical paddle lead, an alternative to percutaneous leads, allowing them to be marketed and sold in the US for spinal cord stimulation, according to a Thursday Australian bourse filing.The firm plans a phased US launch beginning in the second half of the year, with a broader commercial rollout starting later in the year.Its shares soared 18% in recent trading on Tuesday.

ASX:SLD

Asia96d ago

Saluda Medical Unit Receives ASIC Relief From Standalone Financial Reporting Requirements, Shares Up 3%

Saluda Medical (ASX:SLD) said that the Australian Securities and Investments Commission (ASIC) granted relief to its Australian unit, Saluda Medical Pty Ltd, from certain obligations, including the requirement to prepare standalone financial reports, have them audited, and report to members separately, according to a Friday Australian bourse filing.The company said the relief applies from the financial year ended June 30, and each subsequent financial year, with Saluda already preparing consolidated financial statements that include the Australian subsidiary, avoiding the need for separate engagement of Australian accountants and an external auditor.The relief also reduces the risk of shareholders and creditors being misled by separate financial reports, while creditors of the Australian subsidiary will benefit from being party to a deed of cross guarantee (DOCG), it added.The company's shares rose 3% in recent Friday trade.

ASX:SLD

Track with the FINWIRES app suite

FolioX

Track ASX:SLD in your portfolio

WheelAI

Analyze ASX:SLD options with the wheel strategy

StockInsider

See market sentiment on ASX:SLD